Non-additive effects of adjunct erythropoietin therapy with therapeutic hypothermia after global cerebral ischaemia in near-term fetal sheep.
cerebral ischaemia
erythropoietin
fetal sheep
neuroprotection
therapeutic hypothermia
Journal
The Journal of physiology
ISSN: 1469-7793
Titre abrégé: J Physiol
Pays: England
ID NLM: 0266262
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
15
10
2019
accepted:
02
01
2020
pubmed:
9
1
2020
medline:
16
2
2021
entrez:
9
1
2020
Statut:
ppublish
Résumé
Recombinant human erythropoietin (rEpo) is neuroprotective in immature animals, but it is unclear whether the combination of high-dose rEpo therapy with therapeutic hypothermia can further improve outcomes. Hypothermia and rEpo independently improved neuronal survival, with greater improvement with hypothermia, and similarly reduced numbers of caspase-3 positive cells and reactive microglia after 7 days recovery. Hypothermia, but not rEpo, was associated with markedly improved EEG power, whereas both interventions improved recovery of EEG frequency. There was no significant improvement in any outcome after combined rEpo and hypothermia compared with hypothermia alone, and of concern, the combination was associated with increased numbers of cortical caspase-3-positive cells compared with ischaemia-hypothermia. These data suggest that the mechanisms of neuroprotection with hypothermia and rEpo overlap and, thus, high-dose rEpo infusion does not appear to be an effective adjunct therapy for therapeutic hypothermia. Therapeutic hypothermia for hypoxic-ischaemic encephalopathy (HIE) provides incomplete neuroprotection. Recombinant human erythropoietin (rEpo) is neuroprotective in immature animals, but it is unclear whether adjunct rEpo therapy with therapeutic hypothermia can further improve outcomes. Near-term fetal sheep received sham-ischaemia (n = 9) or global cerebral ischaemia for 30 min (ischaemia-vehicle, n = 8), followed by intravenous infusion of rEpo (ischaemia-Epo, n = 8; 5000 U/kg loading dose, then 833.3 U/kg/h), cerebral hypothermia (ischaemia-hypothermia, n = 8), or rEpo plus hypothermia (ischaemia-Epo-hypothermia, n = 8), from 3 to 72 h post ischaemia. Fetal brains were collected 7 days after cerebral ischaemia. Cerebral ischaemia was associated with severe neuronal loss and microglial induction in the parasagittal cortex and subcortical regions. Hypothermia reduced overall neuronal loss, cortical caspase-3 and reactive microglia in the striatum and cortex, with greater recovery of electroencephalographic (EEG) power and spectral edge (SEF) from 48 h onwards. rEpo independently improved neuronal survival in the parasagittal cortex, hippocampal CA4 and thalamus, and reduced cortical caspase-3 and activated microglia in striatal and cortical areas, with greater SEF from 120 h onwards. However, ischaemia-Epo-hypothermia did not further improve outcomes compared with ischaemia-hypothermia and was associated with increased numbers of cortical caspase-3-positive cells. These findings suggest that although delayed, prolonged treatment with both hypothermia and rEpo are independently neuroprotective, they have overlapping anti-inflammatory and anti-apoptotic mechanisms, such that the delayed, high-dose rEpo infusion for 3 days did not materially augment neuroprotection with therapeutic hypothermia.
Substances chimiques
Erythropoietin
11096-26-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
999-1015Informations de copyright
© 2020 The Authors. The Journal of Physiology © 2020 The Physiological Society.
Références
Alexander ML, Hill CA, Rosenkrantz TS & Fitch RH (2012). Evaluation of the therapeutic benefit of delayed administration of erythropoietin following early hypoxic-ischemic injury in rodents. Dev Neurosci 34, 515-524.
Alsalami MT & Filippich LJ (1999). Haematology of foetal sheep. Aust Vet J 77, 588-594.
Azzopardi D, Strohm B, Edwards AD, Halliday H, Juszczak E, Levene M, Thoresen M, Whitelaw A & Brocklehurst P (2009). Treatment of asphyxiated newborns with moderate hypothermia in routine clinical practice: how cooling is managed in the UK outside a clinical trial. Arch Dis Child Fetal Neonatal Ed 94, F260-264.
Azzopardi D, Strohm B, Marlow N, Brocklehurst P, Deierl A, Eddama O, Goodwin J, Halliday HL, Juszczak E, Kapellou O, Levene M, Linsell L, Omar O, Thoresen M, Tusor N, Whitelaw A & Edwards AD (2014). Effects of hypothermia for perinatal asphyxia on childhood outcomes. N Engl J Med 371, 140-149.
Barkovich AJ & Truwit CL (1990). Brain damage from perinatal asphyxia: correlation of MR findings with gestational age. AJNR Am J Neuroradiol 11, 1087-1096.
Baserga MC, Beachy JC, Roberts JK, Ward RM, DiGeronimo RJ, Walsh WF, Ohls RK, Anderson J, Mayock DE, Juul SE, Christensen RD, Loertscher MC, Stockmann C, Sherwin CM, Spigarelli MG & Yoder BA (2015). Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. Pediatr Res 78, 315-322.
Covert RF, Schreiber MD, Torgerson LJ, Torgerson RW & Miletich DJ (1996). Prediction of cerebral blood flow in fetal lambs by carotid artery ultrasonic flow transducer. Reprod Fertil Dev 8, 157-162.
Davidson JO, Draghi V, Whitham S, Dhillon SK, Wassink G, Bennet L & Gunn AJ (2018). How long is sufficient for optimal neuroprotection with cerebral cooling after ischemia in fetal sheep? J Cereb Blood Flow Metab 38, 1047-1059.
Davidson JO, Fraser M, Naylor AS, Roelfsema V, Gunn AJ & Bennet L (2008). Effect of cerebral hypothermia on cortisol and adrenocorticotropic hormone responses after umbilical cord occlusion in preterm fetal sheep. Pediatr Res 63, 51-55.
Davidson JO, Wassink G, van den Heuij LG, Bennet L & Gunn AJ (2015a). Therapeutic hypothermia for neonatal hypoxic-ischemic encephalopathy - Where to from here? Front Neurol 6, 198.
Davidson JO, Wassink G, Yuill CA, Zhang FG, Bennet L & Gunn AJ (2015b). How long is too long for cerebral cooling after ischemia in fetal sheep? J Cereb Blood Flow Metab 35, 751-758.
Dzietko M, Felderhoff-Mueser U, Sifringer M, Krutz B, Bittigau P, Thor F, Heumann R, Buhrer C, Ikonomidou C & Hansen HH (2004). Erythropoietin protects the developing brain against N-methyl-D-aspartate receptor antagonist neurotoxicity. Neurobiol Dis 15, 177-187.
Elmahdy H, El-Mashad AR, El-Bahrawy H, El-Gohary T, El-Barbary A & Aly H (2010). Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics 125, e1135-1142.
El Shimi MS, Awad HA, Hassanein SM, Gad GI, Imam SS, Shaaban HA & El Maraghy MO (2014). Single dose recombinant erythropoietin versus moderate hypothermia for neonatal hypoxic ischemic encephalopathy in low resource settings. J Matern Fetal Neonatal Med 27, 1295-1300.
Elstad M, Whitelaw A & Thoresen M (2011). Cerebral resistance index is less predictive in hypothermic encephalopathic newborns. Acta Paediatr 100, 1344-1349.
Ezzati M, Broad K, Kawano G, Faulkner S, Hassell J, Fleiss B, Gressens P, Fierens I, Rostami J, Maze M, Sleigh JW, Anderson B, Sanders RD & Robertson NJ (2014). Pharmacokinetics of dexmedetomidine combined with therapeutic hypothermia in a piglet asphyxia model. Acta Anaesthesiol Scand 58, 733-742.
Fan X, van Bel F, van der Kooij MA, Heijnen CJ & Groenendaal F (2013). Hypothermia and erythropoietin for neuroprotection after neonatal brain damage. Pediatr Res 73, 18-23.
Fang AY, Gonzalez FF, Sheldon RA & Ferriero DM (2013). Effects of combination therapy using hypothermia and erythropoietin in a rat model of neonatal hypoxia-ischemia. Pediatr Res 73, 12-17.
Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, Polin RA, Robertson CM, Thoresen M, Whitelaw A & Gunn AJ (2005). Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet 365, 663-670.
Grundy D (2015). Principles and standards for reporting animal experiments in The Journal of Physiology and Experimental Physiology. J Physiol 593, 2547-2549.
Gunn AJ, Gunn TR, de Haan HH, Williams CE & Gluckman PD (1997). Dramatic neuronal rescue with prolonged selective head cooling after ischemia in fetal lambs. J Clin Invest 99, 248-256.
Gunn AJ, Laptook AR, Robertson NJ, Barks JD, Thoresen M, Wassink G & Bennet L (2017). Therapeutic hypothermia translates from ancient history in to practice. Pediatr Res 81, 202-209.
Gunn AJ & Thoresen M (2015). Animal studies of neonatal hypothermic neuroprotection have translated well in to practice. Resuscitation 97, 88-90.
Gunn TR, Ball KT, Power GG & Gluckman PD (1991). Factors influencing the initiation of nonshivering thermogenesis. Am J Obstet Gynecol 164, 210-217.
Herz J, Koster C, Reinboth BS, Dzietko M, Hansen W, Sabir H, van Velthoven C, Bendix I & Felderhoff-Muser U (2018). Interaction between hypothermia and delayed mesenchymal stem cell therapy in neonatal hypoxic-ischemic brain injury. Brain Behav Immun 70, 118-130.
Iwai M, Stetler RA, Xing J, Hu X, Gao Y, Zhang W, Chen J & Cao G (2010). Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic/ischemic brain injury. Stroke 41, 1032-1037.
Juul SE, Comstock BA, Heagerty PJ, Mayock DE, Goodman AM, Hauge S, Gonzalez F & Wu YW (2018). High-dose erythropoietin for asphyxia and encephalopathy (HEAL): A randomized controlled trial - background, aims, and study protocol. Neonatology 113, 331-338.
Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ & Gleason CA (2004). Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate 85, 138-144.
Juul SE, Yachnis AT & Christensen RD (1998). Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 52, 235-249.
Kellert BA, McPherson RJ & Juul SE (2007). A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res 61, 451-455.
Kilkenny C, Browne WJ, Cuthill IC, Emerson M & Altman DG (2010). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8, e1000412.
Laptook AR, Corbett RJ, Sterett R, Garcia D & Tollefsbol G (1995). Quantitative relationship between brain temperature and energy utilization rate measured in vivo using 31P and 1H magnetic resonance spectroscopy. Pediatr Res 38, 919-925.
Malla RR, Asimi R, Teli MA, Shaheen F & Bhat MA (2017). Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial. J Perinatol 37, 596-601.
Mosser DM & Edwards JP (2008). Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8, 958-969.
Murray DM, Boylan GB, Ryan CA & Connolly S (2009). Early EEG findings in hypoxic-ischemic encephalopathy predict outcomes at 2 years. Pediatrics 124, e459-e467.
Piuhola J, Kerkela R, Keenan JI, Hampton MB, Richards AM & Pemberton CJ (2008). Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury. Clin Sci 114, 293-304.
Rangarajan V & Juul SE (2014). Erythropoietin: emerging role of erythropoietin in neonatal neuroprotection. Pediatr Neurol 51, 481-488.
Rogers EE, Bonifacio SL, Glass HC, Juul SE, Chang T, Mayock DE, Durand DJ, Song D, Barkovich AJ, Ballard RA & Wu YW (2014). Erythropoietin and hypothermia for hypoxic-ischemic encephalopathy. Pediatr Neurol 51, 657-662.
Roka A, Melinda KT, Vasarhelyi B, Machay T, Azzopardi D & Szabo M (2008). Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy. Pediatrics 121, e844-849.
Shankaran S, Laptook AR, Pappas A, McDonald SA, Das A, Tyson JE, Poindexter BB, Schibler K, Bell EF, Heyne RJ, Pedroza C, Bara R, Van Meurs KP, Huitema CMP, Grisby C, Devaskar U, Ehrenkranz RA, Harmon HM, Chalak LF, DeMauro SB, Garg M, Hartley-McAndrew ME, Khan AM, Walsh MC, Ambalavanan N, Brumbaugh JE, Watterberg KL, Shepherd EG, Hamrick SEG, Barks J, Cotten CM, Kilbride HW & Higgins RD (2017). Effect of depth and duration of cooling on death or disability at age 18 months among neonates with hypoxic-ischemic encephalopathy: A randomized clinical trial. JAMA 318, 57-67.
Smith DC (1992). Effects of skin blood flow and temperature on skin-electrode impedance and offset potential: measurements at low alternating current density. J Med Eng Technol 16, 112-116.
Spasojevic SD, Stojanovic VD, Barisic NA, Doronjski AR, Zikic DR & Babovic SM (2013). Neuroprotective effects of hypothermia and erythropoietin after perinatal asphyxia in newborn rats. J Matern Fetal Neonatal Med 26, 1506-1509.
Tagin MA, Woolcott CG, Vincer MJ, Whyte RK & Stinson DA (2012). Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis. Arch Pediatr Adolesc Med 166, 558-566.
Traudt CM, McPherson RJ, Bauer LA, Richards TL, Burbacher TM, McAdams RM & Juul SE (2013). Concurrent erythropoietin and hypothermia treatment improve outcomes in a term nonhuman primate model of perinatal asphyxia. Dev Neurosci 35, 491-503.
van Bel F, Roman C, Klautz RJ, Teitel DF & Rudolph AM (1994). Relationship between brain blood flow and carotid arterial flow in the sheep fetus. Pediatr Res 35, 329-333.
van Rooij LG, Toet MC, Osredkar D, van Huffelen AC, Groenendaal F & de Vries LS (2005). Recovery of amplitude integrated electroencephalographic background patterns within 24 hours of perinatal asphyxia. Arch Dis Child Fetal Neonatal Ed 90, F245-251.
Wang R, Li J, Duan Y, Tao Z, Zhao H & Luo Y (2017). Effects of erythropoietin on gliogenesis during cerebral ischemic/reperfusion recovery in adult mice. Aging Dis 8, 410-419.
Wassink G, Davidson JO, Dhillon SK, Fraser M, Galinsky R, Bennet L & Gunn AJ (2017). Partial white and grey matter protection with prolonged infusion of recombinant human erythropoietin after asphyxia in preterm fetal sheep. J Cereb Blood Flow Metab 37, 1080-1094.
Wassink G, Davidson JO, Lear CA, Juul SE, Northington F, Bennet L & Gunn AJ (2018). A working model for hypothermic neuroprotection. J Physiol 596, 5641-5654.
Wassink G, Galinsky R, Drury PP, Gunn ER, Bennet L & Gunn AJ (2014). Does maturity affect cephalic perfusion and T/QRS ratio during prolonged umbilical cord occlusion in fetal sheep? Obstet Gynecol Int 2014, 314159.
Wei S, Luo C, Yu S, Gao J, Liu C, Wei Z, Zhang Z, Wei L & Yi B (2017). Erythropoietin ameliorates early brain injury after subarachnoid haemorrhage by modulating microglia polarization via the EPOR/JAK2-STAT3 pathway. Exp Cell Res 361, 342-352.
Williams CE & Gluckman PD (1990). Real-time spectral intensity analysis of the EEG on a common microcomputer. J Neurosci Methods 32, 9-13.
Williams CE, Gunn AJ, Mallard C & Gluckman PD (1992). Outcome after ischemia in the developing sheep brain: an electroencephalographic and histological study. Ann Neurol 31, 14-21.
Williams CE, Gunn AJ, Synek B & Gluckman PD (1990). Delayed seizures occurring with hypoxic-ischemic encephalopathy in the fetal sheep. Pediatr Res 27, 561-565.
Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, Mayock DE, Chang T, Durand DJ, Song D, Bonifacio SL, Gonzalez FF, Glass HC & Juul SE (2012). Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics 130, 683-691.
Wu YW, Mathur AM, Chang T, McKinstry RC, Mulkey SB, Mayock DE, Van Meurs KP, Rogers EE, Gonzalez FF, Comstock BA, Juul SE, Msall ME, Bonifacio SL, Glass HC, Massaro AN, Dong L, Tan KW, Heagerty PJ & Ballard RA (2016). High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: A phase II trial. Pediatrics 137, e20160191.
Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, Ji L, Guo X, Xiong H, Simbruner G, Blomgren K & Wang X (2009). Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 124, e218-226.